TL;DR: Aetna, a CVS Health company, modified CPB 0038 — its allergy and hypersensitivity coverage policy — with an effective date of March 12, 2026. Here's what billing teams need to do.
Aetna's CPB 0038 in the Aetna system governs coverage for allergy testing, immunotherapy, and related hypersensitivity services. This modification signals a potential shift in medical necessity criteria, prior authorization requirements, or covered indications. Because allergy billing touches multiple specialties — allergists, immunologists, ENT, primary care, and pediatrics — this change has broad exposure across your claims.
The full policy text for CPB 0038 is available directly at Aetna's clinical policy bulletins. The specific policy data was not available at time of publication. We'll tell you exactly what that means for your prep work below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Allergy and Hypersensitivity — CPB 0038 |
| Policy Code | CPB 0038 |
| Change Type | Modified |
| Effective Date | March 12, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Allergy/Immunology, ENT, Primary Care, Pediatrics, Internal Medicine |
| Key Action | Pull the current CPB 0038 text from Aetna's site and compare it line by line against your charge capture and prior auth workflows before March 12, 2026 |
Aetna Allergy and Hypersensitivity Coverage Criteria and Medical Necessity Requirements 2026
Aetna's allergy and hypersensitivity coverage policy under CPB 0038 is one of the more consequential clinical policy bulletins for practices that bill allergy services. It sets the medical necessity bar for everything from percutaneous allergy testing to subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).
The full detail of what changed in this March 2026 modification isn't available in the policy data provided. That's not unusual for Aetna — they publish changes to the live bulletin without always flagging a redlined summary. What that means for you: don't assume nothing material changed just because you haven't seen a formal announcement.
Here's what CPB 0038 has historically governed, and where changes tend to land when Aetna modifies this policy.
Allergy Testing Coverage Under CPB 0038
Aetna's allergy testing coverage generally requires that testing be medically necessary to identify specific allergens driving a patient's symptoms. Testing ordered for general wellness screening or without documented clinical history typically fails medical necessity review.
Percutaneous testing — scratch, prick, and puncture methods — has historically been covered when criteria are met. Intradermal testing coverage has been more restricted, particularly when used alone without prior percutaneous testing. If this modification changed the sequencing requirements or added new documentation thresholds, your allergy billing workflows are directly in scope.
Patch testing for contact dermatitis operates under different criteria from inhalant and food allergy testing. If your practice bills both, verify whether CPB 0038 distinguishes between them after this modification.
Immunotherapy Coverage and Medical Necessity
Subcutaneous immunotherapy coverage under Aetna has required documented clinical history, confirmed allergen sensitivity via testing, and failure of or contraindication to avoidance and pharmacotherapy. That bar isn't unusual — it mirrors what most payers require. But the specific sequencing, documentation thresholds, and covered allergen panels can vary significantly by CPB version.
Sublingual immunotherapy is where Aetna's coverage policy has historically been more restrictive. SLIT for most allergens has been considered experimental or investigational under prior versions of CPB 0038, with limited exceptions. If this modification changed SLIT coverage status — in either direction — that's a significant reimbursement event for practices offering it.
Prior authorization requirements for immunotherapy series under Aetna are common. Check whether this modification altered the prior auth trigger points, the required documentation, or the approval duration. A change to the prior auth criteria without a corresponding update to your intake process is a fast path to claim denial.
Biological and Drug-Related Allergy Testing
CPB 0038 also touches drug allergy testing and graded challenge protocols. These have specific medical necessity criteria separate from environmental and food allergen testing. If your practice bills graded drug challenges or drug-specific skin testing, verify whether this section of the policy was affected.
Aetna Allergy and Hypersensitivity Exclusions and Non-Covered Indications
Aetna's allergy coverage policy has historically excluded several categories. Without the specific modification text, we can't confirm which exclusions were added, removed, or revised in this update. But these are the categories most likely to appear in CPB 0038 exclusions — and the ones to verify first.
Unproven or experimental indications in prior CPB 0038 versions have included:
| # | Excluded Procedure |
|---|---|
| 1 | SLIT for most inhalant allergens in most plan types |
| 2 | Provocative neutralization testing |
| 3 | Cytotoxic food testing and ALCAT testing |
| 4 | Serial endpoint titration (SET) beyond diagnostic titration |
| 5 | Applied kinesiology for allergy diagnosis |
| 6 | IgG food sensitivity testing for allergy diagnosis |
If any of these were moved from experimental to covered status — or vice versa — your billing team needs to know before the effective date of March 12, 2026. Billing a service Aetna reclassified as experimental after March 12 will trigger claim denial and may complicate appeals.
Coverage Indications at a Glance
This table reflects the general indication categories under Aetna's allergy and hypersensitivity coverage policy based on CPB 0038 history. Because the specific modification data was not available, confirm each row against the current published policy before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Percutaneous allergy testing (prick/scratch) | Historically Covered | Verify in CPB 0038 | Medical necessity documentation required |
| Intradermal allergy testing | Historically Covered with restrictions | Verify in CPB 0038 | Often requires prior percutaneous testing |
| Patch testing for contact dermatitis | Historically Covered | Verify in CPB 0038 | Separate criteria from inhalant testing |
| Subcutaneous immunotherapy (SCIT) | Historically Covered | Verify in CPB 0038 | Prior authorization commonly required |
| Sublingual immunotherapy (SLIT) | Historically Experimental/Not Covered for most allergens | Verify in CPB 0038 | High priority to check — may have changed |
| Provocative neutralization testing | Historically Not Covered | Verify in CPB 0038 | Considered unproven |
| ALCAT/cytotoxic food testing | Historically Not Covered | Verify in CPB 0038 | Considered unproven |
| IgG food sensitivity testing | Historically Not Covered | Verify in CPB 0038 | Considered unproven for allergy diagnosis |
| Drug allergy testing / graded challenge | Historically Covered with criteria | Verify in CPB 0038 | Specific medical necessity criteria apply |
Aetna Allergy Billing Guidelines and Action Items 2026
The absence of the full modification text doesn't mean you wait. It means you move faster.
| # | Action Item |
|---|---|
| 1 | Pull the current CPB 0038 text now. Go directly to Aetna's clinical policy bulletins at Aetna.com. Pull the March 12, 2026 version and compare it against the previous version. If you don't have the previous version saved, contact Aetna provider relations and request it. You need both to understand what actually changed. |
| 2 | Run a prior authorization audit before March 12, 2026. If this modification changed prior auth triggers for immunotherapy or specific testing categories, authorizations pulled under the old criteria may not hold for services delivered after the effective date. Audit any pending auth requests and any services scheduled after March 12. |
| 3 | Flag SLIT billing for immediate review. Sublingual immunotherapy is the highest-risk line item under CPB 0038. Aetna's historical position has been restrictive on SLIT. If this modification changed that position — in either direction — your charge capture needs to reflect it before you bill a single claim after March 12. |
| 4 | Update your charge capture documentation requirements. Medical necessity documentation for allergy testing and immunotherapy has to match the new criteria exactly. If CPB 0038 now requires specific clinical findings, prior treatment history, or symptom duration in documentation, your intake templates and clinical notes need to reflect that. A claim that gets denied for insufficient medical necessity documentation is harder to appeal than one denied for a simple coding error. |
| 5 | Check your Aetna reimbursement contracts for immunotherapy billing. Some Aetna plan types — HMO, EPO, self-funded — can have plan-level exclusions that layer on top of CPB 0038. Reimbursement rates and coverage rules don't always move in the same direction when a clinical policy bulletin is modified. If your practice has a high Aetna payer mix for allergy services, loop in your billing consultant to verify contract alignment. |
| 6 | Train front desk and authorization staff. If prior authorization requirements changed, the breakdown usually happens at intake — not in the billing office. Make sure the people checking eligibility and submitting auth requests know what changed before March 12, 2026. A same-day patch: pull the new criteria into your auth request checklist. |
| 7 | If your practice bills experimental or borderline services, talk to your compliance officer before the effective date. If CPB 0038 reclassified any service you're currently billing as experimental or investigational, continuing to bill it after March 12 is a compliance exposure. Don't wait for a claim denial to find out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Allergy and Hypersensitivity Under CPB 0038
The policy data provided for this modification did not include specific CPT, HCPCS, or ICD-10 codes. Aetna's CPB 0038 does not list specific codes in this update's available data.
Pull the full CPB 0038 text directly from Aetna's site to get the definitive code list tied to this policy. Historically, allergy and hypersensitivity billing under this type of policy touches CPT codes across allergy testing (percutaneous, intradermal, patch), allergen immunotherapy administration, and allergen preparation — but we won't list codes here that we can't verify against the actual modified policy.
Do not build your charge capture or authorization workflows off a code list that isn't confirmed in the current policy text. This is one of those situations where a 20-minute audit against the live policy document saves you weeks of claim denials and appeals.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.